title: Foam sclerotherapy: cardiac and cerebral monitoring.
abstract: OBJECTIVE
  To investigate and review collected and reported transcutaneous ultrasound, transthoracic echocardiography (TTE) and transcranial Doppler (TCD) data obtained during ultrasound-guided foam sclerotherapy (USGFS) of incompetent saphenous, tributary and perforating veins of the lower extremities.
  
  
  METHODS
  TTE and/or middle cerebral artery TCD were performed during USGFS. Ultrasound (US) findings and adverse events were recorded. Existing literature was reviewed.
  
  
  RESULTS
  Ultrasound detected emboli circulating in superficial, perforating, communicating and deep veins and into the central circulation. TTE detected bright echoes in the right heart after every injection and in the left heart in up to 65% of selected patients. TCD high-intensity transient signals (HITS) were detected in 14-42% of the patients. Incidence of HITS was higher than patient reports of adverse events. Incidence of HITS was independent of foam volumes injected.
  
  
  CONCLUSIONS
  Echogenic signals were detected in non-treated veins, in heart chambers and in the cerebral circulation by transcutaneous US, TTE and TCD. Pathological consequences of such findings remain to be investigated.
authors: Morrison Vein Institute, 8575 E. Princess Dr, Suite 223, Scottsdale, Arizona 85255, USA. nickmorrison2002@yahoo.com
authors: N
authors: N
authors: Morrison
authors: D L
authors: DL
authors: Neuhardt
mesh_terms: D004304:Dosage Forms; D004452:Echocardiography; D004564:Electrocoagulation; D004618:Embolism, Air / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control; D006331:Heart Diseases / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control; D006801:Humans; D020766:Intracranial Embolism / Q000000981:diagnostic imaging / Q000209:etiology* / Q000517:prevention & control; D020768:Middle Cerebral Artery / Q000000981:diagnostic imaging*; D008991:Monitoring, Physiologic; D012501:Saphenous Vein; D012597:Sclerosing Solutions / Q000008:administration & dosage* / Q000009:adverse effects / Q000627:therapeutic use*; D015911:Sclerotherapy / Q000009:adverse effects* / Q000379:methods; D017585:Ultrasonography, Doppler, Transcranial; D018084:Ultrasonography, Interventional; D014648:Varicose Veins / Q000628:therapy*
chemical_list: D004304:Dosage Forms; D012597:Sclerosing Solutions